Tulisokibart — Drug Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

5 Recruiting

5 Completed trials

2 Sponsors

23 Countries

Phase III

Phase II

Phase III: 4 Phase II/III: 1 Phase II: 6

Oversight events:

1 serious breach 1 unexpected event 1 corrective measure across 2 trials

View oversight register →

Indications tested

Ankylosing spondylitis 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 8 Prometheus Biosciences Inc. 3

All trials

11 total

A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown

2025-523766-25-00 Phase III 19 countries Merck Sharp & Dohme LLC
A clinical study of tulisokibart in people with psoriatic arthritis (MK-7240-015) Recruiting

2025-520997-21-00 Phase II 3 countries Merck Sharp & Dohme LLC
A clinical study of tulisokibart to treat radiographic axial spondyloarthritis (MK-7240-013) Recruiting

2025-521059-21-00 Phase II 3 countries Merck Sharp & Dohme LLC
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting

2024-518296-56-00 Phase III 21 countries Merck Sharp & Dohme LLC
A clinical study of tulisokibart in people with Crohn’s disease or ulcerative colitis (MK-7240-011) Recruiting

2024-513533-20-00 Phase III 4 countries Merck Sharp & Dohme LLC
A study of MK-7240/PRA023 in patients with Systemic Sclerosis Associated with Interstitial Lung Disease Recruiting

2023-509743-27-00 Phase II 8 countries Prometheus Biosciences Inc.
A clinical study of tulisokibart in people with rheumatoid arthritis (MK-7240-014) Ended

2025-521745-25-00 Phase II 3 countries Merck Sharp & Dohme LLC
A clinical study of tulisokibart in people with hidradenitis suppurativa (MK-7240-012) Ended

2024-520039-33-00 Phase II/III 5 countries Merck Sharp & Dohme LLC
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Phase III 21 countries Merck Sharp & Dohme LLC
A clinical study of tulisokibart in people with Crohn’s disease (MK-7240-006) Ended

2023-509742-35-00 Phase II 3 countries Prometheus Biosciences Inc.
A clinical study of tulisokibart for the treatment of ulcerative colitis (MK-7240-005) Ended

2023-509741-12-00 Phase II 4 countries Prometheus Biosciences Inc.

Showing 1–11 of 11 trials

← All drugs A–Z